Guest guest Posted October 9, 2009 Report Share Posted October 9, 2009 October 8, 2009 — The US Food and Drug Administration (FDA) has approved an expanded indication for colesevelam HCl tablets and a new powder for oral suspension (Welchol, Daiichi Sankyo, Inc) as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) levels in boys and postmenarchal girls aged 10 to 17 years with heterozygous familial hypercholesterolemia. The bile sequestrant may be used as monotherapy or in combination with a hydroxymethyl-glutaryl-coenzyme A reductase inhibitor (statin) in patients who fail an adequate trial of diet therapy. more: http://www.medscape.com/viewarticle/710136 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.